CombiMatrix Selected by ProPath to Provide CMA Testing for Miscarriage Analysis

Loading...
Loading...
CombiMatrix
CBMX
today announced that it has been selected by ProPath® to provide its chromosomal microarray analysis (CMA) testing for miscarriage analysis for ProPath patients. ProPath, based in Dallas, is a wholly physician-owned provider of pathology services to clinicians, hospitals, reference laboratories and medical facilities nationwide.
See full press release
Market News and Data brought to you by Benzinga APIs
Posted In: NewsGuidanceContractsManagementGlobal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...